Alcatia Pharma Limited iXBRL

Alcatia Pharma Limited

Abridged Unaudited Financial Statements

for the financial period from 11 March 2024 (date of incorporation) to 31 March 2025

ALCATIA PHARMA LIMITED

Company Registration Number: 15554825

ABRIDGED BALANCE SHEET

as at 31 March 2025

Mar 25

Notes

Fixed Assets

Tangible assets

1,927

Investments

20,801

─────────

Current Assets

Debtors

11,702

Cash and cash equivalents

305,949

─────────

317,651

─────────

Creditors: amounts falling due within one year

(33,471)

─────────

Net Current Assets

284,180

─────────

Total Assets less Current Liabilities

306,908

Creditors:

amounts falling due after more than one year

(495,110)

─────────

Net Liabilities

(188,202)

═════════

Capital and Reserves

Called up share capital

Retained earnings

(188,282)

─────────

Shareholders' Deficit

(188,202)

═════════

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).

All of the members have consented to the preparation of abridged accounts in accordance with section 444(2A) of the Companies Act 2006.

The company has taken advantage of the exemption under section 444 not to file the Abridged Profit and Loss Account and Directors' Report.

For the financial period from 11 March 2024 (date of incorporation) to 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.

The directors confirm that the members have not required the company to obtain an audit of its financial statements for the financial period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial period and of its profit and loss for the financial period in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Approved by the Board and authorised for issue on 4 December 2025 and signed on its behalf by




________________________________			________________________________
Julian Wolfe			Kevin Wolfe
Director			Director

ALCATIA PHARMA LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

FOR THE FINANCIAL PERIOD FROM 11 MARCH 2024 (DATE OF INCORPORATION) TO 31 MARCH 2025

General Information

Alcatia Pharma Limited is a company limited by shares incorporated and registered in the United Kingdom. The registered number of the company is 15554825. The registered office of the company is Kingshill Farm, Watchet Lane, Little Kingshill, Great Missenden, Buckinghamshire, HP16 0DR which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Pound (£) which is also the functional currency of the company.

Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial period ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention.

Consolidated accounts

The company is entitled to the exemption in Section 399 of the Companies Act 2006 from the obligation to prepare group accounts.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment

25% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Depreciation on additions is calculated pro rata from the month of acquisition so that the charge reflects the period of ownership within the financial year. Assets disposed of during the year are depreciated up to the date of disposal.

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related tax credit is recognised in the Profit and Loss Account in the financial period in which it is receivable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial period and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

Period of financial statements

The financial statements are for the 12 month 21 days period from 11 March 2024 (date of incorporation) to 31 March 2025.

Going concern

The financial statements have been prepared on a going concern basis. At the year end the company had net liabilities and was dependent on the continued financial support of its directors, who have advanced funds totalling £495,110 to the company.

These loans are unsecured, interest-free, and repayable on demand. The directors have confirmed that they will not seek repayment of these balances within at least 12 months from the date of approval of these financial statements and will continue to provide financial support to enable the company to meet its liabilities as they fall due.

On this basis, the directors consider that it is appropriate to prepare the financial statements on a going concern basis.

Employees

The average monthly number of employees, including directors, during the financial period was 0, (Mar 24 - 0).


6.	Tangible assets
		Fixtures,	Total
		fittings and
		equipment
		£	£
	Cost
	At 11 March 2024	-	-
	Additions	2,126	2,126
		─────────	─────────
	At 31 March 2025	2,126	2,126
		─────────	─────────
	Depreciation
	At 11 March 2024	-	-
	Charge for the financial period	199	199
		─────────	─────────
	At 31 March 2025	199	199
		─────────	─────────
	Net book value
	At 31 March 2025	1,927	1,927
		═════════	═════════


7.	Investments
		Group and	Total
		participating
		interests/
		joint ventures
	Investments	£	£
	Cost
	Additions	20,801	20,801
		─────────	─────────
	At 31 March 2025	20,801	20,801
		─────────	─────────
	Net book value
	At 31 March 2025	20,801	20,801
		═════════	═════════

7.1.

Holdings in related undertakings

The company holds 20% or more of the share capital of the following company:

Country

Nature

Details

Proportion

held by

Name

incorporation and address of Registered Office

business

investment

company

Subsidiary undertaking

Alcatia Pharma GmbH

Rheinstrasse 11

D-14513 Teltow

Potsdam

Germany

Dormant

Ordinary

100

In the opinion of the directors, the value to the company of the unlisted investments is not less than the book amount shown above.

Capital commitments

The company had no material capital commitments at the financial period-ended 31 March 2025.

Post-Balance Sheet Events

There have been no significant events affecting the company since the financial period-end.